Genflow Biosciences PLC Announces Result of GM
-
Tourists trickle back to Kashmir, one year after deadly attack
-
Inside the world of ultra-luxury wedding cakes
-
Chinese AI circuit board maker soars on Hong Kong debut
-
Oil prices dip, most stocks rise on lingering Iran peace hopes
-
Tim Cook's time as Apple chief marked by profit absent awe
-
Mitchell, Harden shine as Cavs down Raptors for 2-0 series lead
-
El Salvador's missing thousands buried by official indifference
-
Trump's Fed chair pick to face lawmakers at key confirmation hearing
-
PGA Tour to scrap Hawaii opening events from 2027
-
Amazon invests another $5 bn in Anthropic
-
Israel PM vows 'harsh action' against soldier vandalising Jesus statue in Lebanon
-
Wembanyama wins NBA defensive player of the year
-
'The Devil Wears Prada 2' stars reunite for glamorous premiere
-
El Salvador holds mass trial of nearly 500 alleged gang members
-
Apple's Tim Cook to step down as CEO in September
-
West Ham's draw at Palace relegates Wolves, piles pressure on Spurs
-
Canadian tourist killed in Mexico archaeological site shooting
-
Wolves relegated from Premier League
-
Oil jumps on Hormuz tensions, stocks mostly retreat
-
Colombian environmental activist honored amid threats and exile
-
Gun battle traps more than 200 tourists at Rio viewpoint
-
Alcaraz may skip French Open rather than rush injury comeback
-
Top US court to hear case of Catholic schools excluded from state funding
-
Trump Fed chair pick to vow interest rate independence at key hearing
-
EU to host Taliban officials for talks on deporting Afghans
-
Blue Origin probing rocket's failure to deliver satellite
-
Pope blasts 'exploitation' as he wraps up tour of Angola
-
Wembanyama 'changing the game as we speak', says Nowitzki
-
Singer D4vd charged with murder after teen's body found in Tesla
-
Swiss football club turn down Kanye West concert approach
-
Leicester fairytale turns sour as relegation to third tier looms
-
Pope Leo blasts 'exploitation' as he wrap up tour of resource-rich Angola
-
Varma ton revives Mumbai's IPL hopes with win over Gujarat
-
Formula One makes rule changes after drivers' criticism
-
Singer D4vd charged with murder over teen's body found in Tesla
-
UK PM denies misleading MPs, says officials hid Mandelson info
-
Tit-for-tat blockades once again cripple traffic in Hormuz
-
Cafu says 2026 World Cup is perfect time for Brazil to win again
-
Erdogan vows new measures after deadly Turkey school shootings
-
Rose to take charge at Bournemouth after Iraola exit
-
Olympic status a massive 'boost' for squash says European champion Crouin
-
Kenyan double-double as Korir, Lokedi defend Boston Marathon crowns
-
Whale stranded on German coast swims off, gets stuck again
-
Iran pulling Hormuz 'lever' to maximum in US standoff
-
Argentine film and theater great Luis Brandoni dies at 86
-
French Open sensation Boisson returns to action after 'most difficult' spell
-
Desmond Morris: from 'Naked Ape' to watching 'Big Brother'
-
Rosenior says Chelsea owners supportive despite slump
-
Oil jumps on Hormuz tensions, stocks retreat
-
Romania legend Hagi eyes 'winning every game' on return as coach
Genflow Biosciences PLC Announces Result of GM
Results of General Meeting
LONDON, UK / ACCESS Newswire / March 2, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") a leading European-based biotechnology company focusing on longevity, is pleased to announce that all resolutions proposed at the General Meeting held earlier today were duly passed by shareholders. The number of proxy votes for each resolution submitted prior to the meeting are presented below.
Proxy Voting Results
Ordinary Resolutions | Votes for | % of votes cast for | Votes Against | % of votes cast against | Votes withheld | Total votes cast |
1. To approve the Director's authority to allot securities. | 224,571,419 | 98.2% | 3,787,114 | 1.7% | 429,987 | 228,788,520 |
Special Resolution | Votes for | % of votes cast for | Votes Against | % of votes cast against | Votes withheld | Total votes cast |
2. To disapply statutory pre-emption rights. | 222,245,570 | 97.1% | 5,141,463 | 2.2% | 1,401,487 | 228,788,520 |
Contacts Genflow Biosciences | Harbor Access |
Dr Eric Leire, CEO | Jonathan Paterson, Investor Relations |
+32-477-495-881 | +1 475 477 9401 |
About Genflow
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, delivers a proprietary centenarian variant of the SIRT6 gene. The therapy is currently being evaluated in the Company's randomised, blinded SLAB (Sarcopenia and Longevity in Aged Beagles) study in dogs aged over 10 years, which commenced in March 2025. Preliminary interim results demonstrated improved survival versus control during the dosing period, alongside favourable safety and tolerability and positive trends across functional endpoints including muscle mass preservation, frailty reduction and quality of life. Other programs include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and X.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on ACCESS Newswire
L.Durand--AMWN